<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>14(16)</volume><submitter>Cheng K</submitter><pubmed_abstract>C-X-C motif chemokine receptor 4 (CXCR4) is an attractive target for the diagnosis and treatment of cancers. Here, we aimed to develop a new CXCR4-targeted PET tracer, and to investigate the translational potential for noninvasive imaging of CXCR4 expression in various cancer entities through preclinical and pilot clinical studies. &lt;b>Methods&lt;/b> [&lt;sup>18&lt;/sup>F]AlF-NOTA-QHY-04 was synthesized and evaluated by cellular uptake, blocking and biolayer interferometry studies &lt;i>in vitro&lt;/i>. The pharmacokinetics, biodistribution, and imaging specificity were researched in tumor-bearing mice. [&lt;sup>18&lt;/sup>F]AlF-NOTA-QHY-04 PET/CT imaging was performed on 55 patients with different types of cancers. Correlations between &lt;i>ex vivo&lt;/i> CXCR4 expression and PET parameters, and CXCR4 expression ch</pubmed_abstract><journal>Theranostics</journal><pagination>6337-6349</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11488100</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>PET imaging of CXCR4 expression using [&amp;lt;sup&amp;gt;18&amp;lt;/sup&amp;gt;F]AlF-NOTA-QHY-04 for hematologic malignancy and solid tumors.</pubmed_title><pmcid>PMC11488100</pmcid><pubmed_authors>Liu J</pubmed_authors><pubmed_authors>Wang S</pubmed_authors><pubmed_authors>Cheng K</pubmed_authors><pubmed_authors>Pei J</pubmed_authors><pubmed_authors>Xu S</pubmed_authors><pubmed_authors>Luo Y</pubmed_authors><pubmed_authors>Liu T</pubmed_authors><pubmed_authors>Zhao K</pubmed_authors><pubmed_authors>Yu J</pubmed_authors></additional><is_claimable>false</is_claimable><name>PET imaging of CXCR4 expression using [&amp;lt;sup&amp;gt;18&amp;lt;/sup&amp;gt;F]AlF-NOTA-QHY-04 for hematologic malignancy and solid tumors.</name><description>C-X-C motif chemokine receptor 4 (CXCR4) is an attractive target for the diagnosis and treatment of cancers. Here, we aimed to develop a new CXCR4-targeted PET tracer, and to investigate the translational potential for noninvasive imaging of CXCR4 expression in various cancer entities through preclinical and pilot clinical studies. &lt;b>Methods&lt;/b> [&lt;sup>18&lt;/sup>F]AlF-NOTA-QHY-04 was synthesized and evaluated by cellular uptake, blocking and biolayer interferometry studies &lt;i>in vitro&lt;/i>. The pharmacokinetics, biodistribution, and imaging specificity were researched in tumor-bearing mice. [&lt;sup>18&lt;/sup>F]AlF-NOTA-QHY-04 PET/CT imaging was performed on 55 patients with different types of cancers. Correlations between &lt;i>ex vivo&lt;/i> CXCR4 expression and PET parameters, and CXCR4 expression ch</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024</publication><modification>2025-04-04T19:45:45.129Z</modification><creation>2025-04-04T19:45:45.129Z</creation></dates><accession>S-EPMC11488100</accession><cross_references><pubmed>39431004</pubmed><doi>10.7150/thno.99025</doi></cross_references></HashMap>